After suspending the proposed clinical trials of Bharat Biotech’s Covid-19 vaccine Covaxin, Brazil has now scrapped the firm’s Emergency Use Authorisation request. Anvisa, the National Health Surveillance Agency of Brazil, said, “The decision was taken after Anvisa was informed by the Indian company Bharat Biotech International Limited that the company Necessidade no longer has authorisation to represent Bharat Biotech, manufacturer of the Covaxin vaccine, in Brazil.”

Bharat Biotech had said on July 23 that it terminated the MoU with Precisa Medicamentos and Envixia Pharmaceuticals LLC for Covaxin for Brazilian market. The termination of the MoU came after the deal with the Brazilian government for supply of 20 million doses of Covaxin landed in controversy and attracted investigation by authorities in that country. The Brazilian government had earlier temporarily suspended Covaxin’s order following the graft allegations and subsequent inquiry by the authorities.